RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Amino-Ended Hyperbranched Polyamide Modified SBA-15 as Support for Highly Efficient Cobalt Fischer-Tropsch Synthesis Catalyst

        Sufang Chen,Yanju Qiu,Xixi Xing,Cunwen Wang,Chengchao Liu,Yuhua Zhang,Jingping Hong,Jinlin Li,Daohong Zhang 한국고분자학회 2020 Macromolecular Research Vol.28 No.3

        Among the Fischer-Tropsch synthesis (FTS) catalysts, Cobalt catalysts are currently attracting a lot of research interests due to their high activity and high selectivity. But the dispersion and reducibility of cobalt catalysts with moderate interaction between cobalt and support are still a challenge. A novel amino-ended hyperbranched polyamide (AEHPA) was used to modify SBA-15 and then was applied as support for obtaining cobalt catalyst (15Co/SBA-15-N). The catalysts were characterized by XRD, TEM, XPS and H2-TPR techniques. The results showed that AEHPA doped mesoporous SBA-15 caused the generation of N species in the SBA-15 pore channels. The N-Co bonds resulted in the formation of highly-dispersed cobalt nanoparticles with uniform sizes inside the ordered mesopores of support. AEHPA doping was an effective way to modify the surface properties of the SBA-15 for immobilizing cobalt nanoparticles. Compared with the conventional 15Co/SBA-15 catalyst without doping AEHPA, the AEHPA doped 15Co/SBA-15-N catalyst showed improved cobalt dispersion and stabilized cobalt location, which led to much better reaction stability as well as C5+ selectivity.

      • KCI등재

        Determination of thermo-elastic parameters for dynamical modeling of 2.5D C/SiC braided composites

        Sufang Chen,Qingguo Fei,Dong Jiang,Zhifu Cao 대한기계학회 2018 JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY Vol.32 No.1

        An approach on determining elastic parameters and Coefficient of thermal expansion (CTE) of a 2.5-dimensional (2.5D) braided composites is proposed in this paper, by adopting mesoscopic mechanics integrated Finite element (FE) modeling. According to the geometric features of meso-structure, Representative volume cell (RVC) models of composite for predicting thermo-elastic parameters are established. On the basis of the models, homogenized parameter prediction is carried out in three steps: Firstly, equivalent elastic properties is predicted subject to periodic displacement boundary conditions; secondly, the equivalent thermal modulus is determined by using the periodic non-adiabatic temperature boundary conditions; thirdly, using the obtained elastic parameters and thermal modulus to calculate the equivalent coefficient of thermal expansion. A multiscale finite element analysis is conducted: The thermo-elastic parameters of yarn is calculated using the RVC model; subsequently, the equivalent parameters of the yarn are substituted into the RVC of 2.5D braided C/SiC composites, to predict the thermo-elastic parameters. Results indicate that the CTE determined by homogenized parameter prediction of 2.5D C/SiC composites shows good agreements with the experimental results. At last, the refined FE model and the equivalent homogeneous model are employed to verify the effectiveness of the predicted parameters in terms of effective modeling. After the comparative analysis on thermal modal data between refined model and equivalent model, the acquired results demonstrate the effectiveness of the proposed method in determining thermo-elastic parameters.

      • KCI등재

        A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

        Ting-Yan Shi,Sheng Yin,Jianqing Zhu,Ping Zhang,Jihong Liu,Libing Xiang,Yaping Zhu,Sufang Wu,Xiaojun Chen,Xipeng Wang,Yin-Cheng Teng,Tao Zhu,Aijun Yu,Yingli Zhang,Yanling Feng,He Huang,Wei Bao,Yanli Li 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.3

        Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence. Methods: SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography–computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cycles of platinum-based chemotherapy and niraparib maintenance or 6 cycles of platinum-based chemotherapy and niraparib maintenance alone. Patients who undergo at least 4 cycles of chemotherapy and must be, in the opinion of the investigator, without disease progression, will be assigned niraparib maintenance. Major inclusion criteria are secondary relapsed OC with a platinum-free interval of no less than 6 months and a possibly complete resection. Major exclusion criteria are borderline tumors and non-epithelial ovarian malignancies, received debulking surgery at recurrence and impossible to complete resection. The sample size is 96 patients. Primary endpoint is 12-month non-progression rate. Trial Registration: ClinicalTrials.gov Identifier: NCT03983226

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼